Shenzhen Kaifa Technology
920029
Shanghai Yongli Belting
300230
Guomai Culture & Media
301052
4
WuHan Hvsen Biotechnology
300871
5
CHANGFU CO.,LTD
871396
US Stock MarketDetailed Quotes
ADAP Adaptimmune Therapeutics
- 0.206
- -0.014-6.36%
Close Mar 28 16:00 ET
- 0.210
- +0.004+1.87%
Post 20:01 ET
52.99MMarket Cap-0.69P/E (TTM)
0.237High0.203Low2.97MVolume0.237Open0.220Pre Close638.30KTurnover1.69%Turnover RatioLossP/E (Static)257.23MShares1.55052wk High4.48P/B36.15MFloat Cap0.20352wk Low--Dividend TTM175.46MShs Float21.570Historical High--Div YieldTTM15.68%Amplitude0.203Historical Low0.215Avg Price1Lot Size
Adaptimmune Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 195.34%178.03M | 1,294.81%3.22M | 458.83%40.9M | 2,399.63%128.23M | -88.07%5.68M | 122.05%60.28M | -97.91%231K | 4.45%7.32M | -7.37%5.13M | 1,231.50%47.6M |
| Operating revenue | 195.34%178.03M | 1,294.81%3.22M | 458.83%40.9M | 2,399.63%128.23M | -88.07%5.68M | 122.05%60.28M | -97.91%231K | 4.45%7.32M | -7.37%5.13M | 1,231.50%47.6M |
| Cost of revenue | 70K | 0 | ||||||||
| Gross profit | 195.22%177.96M | 122.05%60.28M | ||||||||
| Operating expense | 16.16%230.37M | 20.43%60.32M | 3.02%55.58M | 18.97%59.53M | 24.18%54.94M | 3.77%198.32M | 30.88%50.09M | 7.91%53.95M | 1.52%50.04M | -17.39%44.24M |
| Selling and administrative expenses | 13.23%81.31M | 25.71%21.22M | 31.63%21.28M | -4.93%19.08M | 5.55%19.73M | 13.29%71.81M | 10.91%16.88M | -3.87%16.16M | 37.96%20.07M | 11.25%18.69M |
| -Selling and marketing expense | --506K | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| -General and administrative expense | 12.53%80.81M | 22.71%20.71M | 31.63%21.28M | -4.93%19.08M | 5.55%19.73M | 13.29%71.81M | 10.91%16.88M | -3.87%16.16M | 37.96%20.07M | 11.25%18.69M |
| Research and development costs | 17.83%149.06M | 17.75%39.1M | -9.22%34.3M | 34.98%40.45M | 37.81%35.21M | -0.95%126.51M | 44.06%33.21M | 13.88%37.79M | -13.74%29.97M | -30.49%25.55M |
| Operating profit | 62.03%-52.41M | -14.67%-57.17M | 68.52%-14.68M | 252.98%68.7M | -1,566.54%-49.26M | 15.81%-138.04M | -83.01%-49.86M | -8.47%-46.63M | -2.64%-44.91M | 106.72%3.36M |
| Net non-operating interest income expense | -45.54%3.25M | -95.86%66K | -54.07%987K | -44.91%850K | 98.96%1.35M | 286.77%5.96M | 205.16%1.6M | 563.27%2.15M | 332.21%1.54M | 100.00%676K |
| Non-operating interest income | 10.60%6.6M | 11.47%1.78M | -2.47%2.1M | -10.82%1.38M | 98.96%1.35M | 286.77%5.96M | 205.16%1.6M | 563.27%2.15M | 332.21%1.54M | 100.00%676K |
| Non-operating interest expense | --3.35M | --1.71M | --1.11M | --526K | ---- | --0 | --0 | --0 | --0 | ---- |
| Other net income (expense) | -192.52%-18.08M | -4,826.52%-15.42M | -619.30%-3.09M | -97.81%497K | 97.43%-61K | 3,745.34%19.54M | 79.64%-313K | -126.16%-430K | 3,558.93%22.66M | -19,883.33%-2.37M |
| Special income (charges) | -180.36%-16.35M | ---16.35M | --0 | --0 | --0 | --20.35M | --0 | ---106K | --22.16M | ---1.7M |
| -Less：Restructuring and merger&acquisition | 129.24%5.95M | --5.95M | --0 | --0 | --0 | ---20.35M | --0 | --106K | ---22.16M | --1.7M |
| -Less:Impairment of capital assets | --10.4M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Other non- operating income (expenses) | -113.88%-1.73M | 397.44%931K | -854.63%-3.09M | -0.80%497K | 90.91%-61K | -50.56%-807K | 79.64%-313K | -119.71%-324K | 176.49%501K | -5,691.67%-671K |
| Income before tax | 40.25%-67.24M | -49.31%-72.52M | 62.63%-16.79M | 438.24%70.05M | -2,988.44%-47.98M | 30.94%-112.54M | -71.90%-48.57M | -9.49%-44.91M | 52.99%-20.71M | 103.35%1.66M |
| Income tax | 167.66%3.58M | 358.08%1.69M | 20.96%831K | -22.65%526K | -15.84%526K | -46.50%1.34M | -166.00%-656K | 72.18%687K | 44.68%680K | -1.42%625K |
| Net income | 37.81%-70.81M | -54.88%-74.22M | 61.37%-17.62M | 425.03%69.52M | -4,781.76%-48.5M | 31.18%-113.87M | -63.82%-47.92M | -10.09%-45.6M | 51.96%-21.39M | 102.06%1.04M |
| Net income continuous Operations | 37.81%-70.81M | -54.88%-74.22M | 61.37%-17.62M | 425.03%69.52M | -4,781.76%-48.5M | 31.18%-113.87M | -63.82%-47.92M | -10.09%-45.6M | 51.96%-21.39M | 102.06%1.04M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 37.81%-70.81M | -54.88%-74.22M | 61.37%-17.62M | 425.03%69.52M | -4,781.76%-48.5M | 31.18%-113.87M | -63.82%-47.92M | -10.09%-45.6M | 51.96%-21.39M | 102.06%1.04M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 37.81%-70.81M | -54.88%-74.22M | 61.37%-17.62M | 425.03%69.52M | -4,781.76%-48.5M | 31.18%-113.87M | -63.82%-47.92M | -10.09%-45.6M | 51.96%-21.39M | 102.06%1.04M |
| Basic earnings per share | 44.44%-0.3 | -74.19%-0.3135 | 66.67%-0.06 | 350.00%0.3 | -2,970.81%-0.18 | 47.06%-0.54 | 0.00%-0.18 | 25.00%-0.18 | 60.00%-0.12 | 102.09%0.0063 |
| Diluted earnings per share | 44.44%-0.3 | -74.19%-0.3135 | 66.67%-0.06 | 300.00%0.24 | -2,996.68%-0.18 | 47.06%-0.54 | 0.00%-0.18 | 25.00%-0.18 | 60.00%-0.12 | 102.07%0.0062 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Market Insights
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025